摘要
背景:紫杉醇于1993年获得批准,标志着萜类化合物在抗癌领域的广泛应用,在治疗难治性卵巢、乳腺癌和难治性卵巢癌方面仍具有重要意义。她的癌症。几十年来,其他突出的天然萜类化合物已成为现代乳腺癌药物治疗不可缺少的物质。然而,鉴于耐药性的快速演变,对需要细胞毒性化疗的晚期乳腺癌的治疗是一个主要的未得到满足的临床需要。因此,迫切需要有效的长效化疗药物. 目的:综述2012年1月1日至2016年12月31日期间天然萜类化合物的研究进展及其防治女性乳腺癌的机制。 结果:癌变是一个多步骤的过程,每一个阶段都表现出明显的表型变化。这次审查中记录的许多化学品被证明是非常重要的。体外和体内抑制不同乳腺癌细胞/肿瘤的增殖、迁移、抗凋亡、抑制肿瘤血管生成或转移。同时瞄准几个或所有这些癌症的进展可能是一种优势。据此,植物化物,如胸腺醌(8),肋古诺内酯(46),丹参酮IIA(132),雷公藤内酯醇(136),葫芦素B(179),细胞星形胶质(226)和番茄红素(238)引起了我们的注意。 结论:这些化合物有望克服乳腺癌的治疗失败。然而,尽管这些活动令人感兴趣,但还需要进一步的临床前研究。乳腺癌细胞/肿瘤模型的体外和体内研究。
关键词: 乳腺癌,抗癌,萜类化合物,致癌,乳腺癌治疗。
Current Medicinal Chemistry
Title:Natural Terpenoids Against Female Breast Cancer: A 5-year Recent Research
Volume: 25 Issue: 27
关键词: 乳腺癌,抗癌,萜类化合物,致癌,乳腺癌治疗。
摘要: Background: The approval of Taxol® in 1993 marked the great entrance of terpenoids in the anti-cancer area and this drug is still highly important in the treatment of refractory ovarian, breast and other cancers. Over decades, other prominent natural terpenoids have become indispensable for the modern pharmacotherapy of breast cancer. However, given the rapid evolution of drug resistance, effective treatments for advanced breast cancers requiring cytotoxic chemotherapy represent a major unmet clinical need. Therefore, innovative agents effective in long-term chemotherapy are urgently needed.
Objective: This review examines recent advances/research about natural terpenoids, and their mechanisms against female breast cancer over the period covering January 1st, 2012 to December 31st, 2016.
Results: Carcinogenesis constitutes a multistep process wherein each stage is characterized by distinct phenotypic changes. Numerous chemicals recorded in this review have been shown to significantly inhibit proliferation, migration, apoptosis resistance, tumor angiogenesis or metastasis in different breast cancer cells/tumours in vitro and in vivo. Targeting simultaneously several or all these aspects/steps of cancer progression could be an advantage. In line with this, phytochemicals such as thymoquinone (8), costunolide (46), tanshinone IIA (132), triptolide (136), cucurbitacin B (179), celastrol (226) and lycopene (238) had caught our attention.
Conclusion: These compounds appear to be promising to overcome breast cancer treatment failure. However, despite the interesting activities, additional preclinical investigations are needed in further breast cancer cell/tumor models in vitro and in vivo.
Export Options
About this article
Cite this article as:
Natural Terpenoids Against Female Breast Cancer: A 5-year Recent Research, Current Medicinal Chemistry 2018; 25 (27) . https://dx.doi.org/10.2174/0929867325666180214110932
DOI https://dx.doi.org/10.2174/0929867325666180214110932 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry Meta-analysis of NFKB1-94 ATTG Ins/Del Polymorphism and Risk of Breast Cancer
Current Drug Metabolism Exploring the Molecular Function of PIN1 by Nuclear Magnetic Resonance
Current Protein & Peptide Science Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line
Protein & Peptide Letters Selective Internal Radiation Therapy with Yttrium-90 for Unresectable Liver Tumours
Reviews on Recent Clinical Trials Breast Cancer Targeted Treatment Strategies: Promising Nanocarrier Approaches
Anti-Cancer Agents in Medicinal Chemistry Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Development and Evaluation of Bioresponsive Tablets of a Selective COX-2 Inhibitor for Colonic Delivery
Drug Delivery Letters AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry